Medicure announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Aggrastat (tirofiban HCl) injection to expand the product’s dosing time.

The newly approved labeling supplement now allows the delivery duration of Aggrastat high-dose bolus (25mcg/kg) to occur anytime within five minutes, rather than the previously specified duration of over three minutes.

RELATED: Invasive Strategy Improves Outcome in Elderly With ACS

Aggrastat is platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

For more information visit